Axogen, Inc. Common Stock
AXGNAxogen, Inc. is a biotechnology company focused on the development and commercialization of surgical grafts to repair, replace, or regenerate peripheral nerve tissue. The company specializes in products aimed at nerve repair and regeneration, providing solutions for nerve injuries resulting from surgery, trauma, and other conditions. Based in Florida, Axogen aims to improve functional outcomes for patients with nerve damage.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 12, 2010 | $1.00 | 2010-01-27 | 2010-01-29 |
| March 11, 2005 | $0.06 | 2005-02-23 | 2005-02-25 |
Dividends Summary
- Consistent Payer: Axogen, Inc. Common Stock has rewarded shareholders with 2 dividend payments over the past 5 years.
- Total Returned Value: Investors who held AXGN shares during this period received a total of $1.06 per share in dividend income.
- Latest Payout: The most recent dividend of $1.00/share was paid 5824 days ago, on February 12, 2010.
- Dividend Growth: Since 2005, the dividend payout has grown by 1566.7%, from $0.06 to $1.00.
Company News
Axogen, Inc. announced an upsized underwritten public offering of 4 million shares at $31.00 per share, expected to raise approximately $124 million in gross proceeds. The company plans to use the net proceeds to pay off its term loan facility with Oberland Capital, along with working capital and capital expenditures. The offering is expected to ...
Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by a...
Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.
The Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.
The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.
